Literature DB >> 6342390

The endocrine manifestations of hemochromatosis.

L W McNeil, L C McKee, D Lorber, D Rabin.   

Abstract

We have evaluated the endocrine changes in 10 male subjects with hemochromatosis. Two subjects initially had aplastic anemia, and the remainder had idiopathic hemochromatosis. Four of the ten patients had diabetes mellitus. Sexual dysfunction (impotence and/or decreased libido) was observed in 8 subjects. Six patients had subnormal testosterone levels; FSH levels were almost uniformly low, but LH concentrations were more variable. Only three patients had normal testosterone responses to hCG. Hypothyroidism, free T4 less than 0.9 ng/dl, was present in 4 subjects, and the etiology was heterogeneous. Basal prolactin levels were elevated in 2 patients and failed to respond adequately to TRH in 2 other patients. Growth hormone reserve was normal in all but 1 patient, and pituitary-adrenal reserve was normal in all but 1 patient. We conclude that disturbances in both pituitary and end-organ function are observed in hemochromatosis. These central and end-organ defects may exist alone or simultaneously. Hypogonadism is almost universal, and is a consequence of defective function of the hypothalamic-pituitary axis and/or primary Leydig cell disturbance. Other evidence of pituitary disturbance are observed but are rather uncommon.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342390     DOI: 10.1097/00000441-198305000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  12 in total

1.  Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction.

Authors:  A Piperno; M R Rivolta; R D'Alba; S Fargion; F Rovelli; A Ghezzi; M Micheli; G Fiorelli
Journal:  J Endocrinol Invest       Date:  1992-06       Impact factor: 4.256

2.  Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement.

Authors:  K Siminoski; M D'Costa; P G Walfish
Journal:  J Endocrinol Invest       Date:  1990-11       Impact factor: 4.256

Review 3.  The mechanisms of systemic iron homeostasis and etiology, diagnosis, and treatment of hereditary hemochromatosis.

Authors:  Hiroshi Kawabata
Journal:  Int J Hematol       Date:  2017-11-13       Impact factor: 2.490

Review 4.  Overview of hemochromatosis.

Authors:  L H Smith
Journal:  West J Med       Date:  1990-09

5.  Thyroid function in haemochromatosis.

Authors:  M S Murphy; C H Walsh
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

6.  Mineralocorticoid status and endocrine dysfunction in severe hemochromatosis.

Authors:  L M Hempenius; P S Van Dam; J J Marx; H P Koppeschaar
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

7.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Orthopade       Date:  2010-06       Impact factor: 1.087

Review 8.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

9.  Hypopituitarism in primary haemochromatosis; recovery after iron depletion.

Authors:  R Gama; M J Smith; J Wright; V Marks
Journal:  Postgrad Med J       Date:  1995-05       Impact factor: 2.401

Review 10.  Endocrine dysfunction in hereditary hemochromatosis.

Authors:  C Pelusi; D I Gasparini; N Bianchi; R Pasquali
Journal:  J Endocrinol Invest       Date:  2016-03-07       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.